Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Añadir filtros








Intervalo de año
1.
Rev. Soc. Bras. Med. Trop ; 52: e20180236, 2019. graf
Artículo en Inglés | LILACS | ID: biblio-977116

RESUMEN

Abstract In Brazil, meglumine antimoniate is the first drug of choice for mucosal leishmaniasis treatment followed by amphotericin B and pentamidine isethionate. We report the case of a patient with severe mucosal lesions caused by Leishmania (Viannia) braziliensis that were difficult to treat. Over a 14-year period, the patient showed low adherence and three treatment attempts with meglumine antimoniate failed. Additionally, there was an unsatisfactory response to liposomal amphotericin B and nephrotoxicity when using amphotericin B deoxycholate that persisted after new treatment attempt with liposomal amphotericin B. Finally, healing was achieved with pentamidine isethionate and maintained during nine months of monitoring.


Asunto(s)
Humanos , Masculino , Pentamidina/uso terapéutico , Leishmania braziliensis/efectos de los fármacos , Leishmaniasis Mucocutánea/tratamiento farmacológico , Antiprotozoarios/uso terapéutico , Resultado del Tratamiento , Persona de Mediana Edad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA